EUDA Health (EUDA) announced an acceleration of its longevity and regenerative medicine strategy with the launch of a stem cell therapy platform and establishment of its first clinic in Shenzhen, China. This strategic advancement builds on the Company’s earlier acquisition of distribution rights for T-cell immunotherapies developed by Shenzhen Inno Immune, a developer of autologous cellular therapeutic and customized medicines for a wide range of diseases in China, and its announced intention to acquire GO POSB Organoids, a biotechnology company formed in Singapore.
Claim 70% Off TipRanks Premium
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on EUDA:
- EUDA Health Integrates QB Utility Token Into Digital Health and Rewards Platform
- EUDA Health to introduce QB utility token into health, rewards platform
- EUDA Health Cuts Warrant Exercise Price in December Funding Adjustment
- EUDA Health Holdings to Launch QB Utility Token in Healthcare Ecosystem
- EUDA Health plans to integrate QB utility token into healthcare ecosystem